This report comes with 10% free customization, enabling you to add data that meets your specific business needs.
The global viral and non-viral vector manufacturing market was valued at $1.50 billion in 2020 and is expected to reach $27.03 billion by 2031, witnessing a CAGR of 18.54% during the forecast period 2021-2031.
Market Report Coverage - Viral and Non-Viral Vector Manufacturing
Market Segmentation
- Vector Type – Viral Vector and Non-Viral Vector
- Disease – Cancer, Genetic Disease, Infectious Disease, Cardiovascular Disease, Other Diseases
- Application – Gene Therapy, Vaccinology, Cell Therapy, and Other Applications
Regional Segmentation
- North America: U.S., Canada
- Europe: Germany, U.K., France, Italy, Switzerland, Belgium, Spain, and Rest-of-Europe
- Asia-Pacific: China, India, Japan, Australia, South Korea, Singapore, and Rest-of-Asia-Pacific
- Rest-of-the-World
Market Growth Drivers
- Rapid Uptake of Viral Vector to Develop Innovative Therapies
- Increasing Number of Clinical Studies for the Development of Gene Therapy
- Favorable Funding Scenario for Vector-Based Therapies
- Increasing Adoption of Nucleic Acid Therapeutics
- Rise in Synergistic Activities in the Market
Market Challenges
- Unaffordable Cost of Gene Therapy
- High Manufacturing Cost of Viral Vectors
- Complications Associated with Large-Scale Production of Viral Vectors
- Low Transfection Efficiency
Market Opportunities
- Rise in Demand for Synthetic Genes
- Emergence of Next-Generation Vectors
- Limitation of Viral Vectors
Key Companies Profiled
Boehringer Ingelheim, Catalent, Inc., FUJIFILM Holdings Corporation, Danaher Corporation, Genscript Biotech Corporation, Lonza Group AG, Merck KGaA Inc., Oxford Biomedica plc, Sartorius AG, Takara Bio Inc., Thermo Fisher Scientific Inc., Wuxi AppTec, Acuitas Therapeutics, Evonik Industries AG, Exelead, Inc., Entos Pharmaceuticals, Genevant Sciences GmbH, T&T Scientific Corporation, Moderna, Inc., CureVac N.V.
Key Questions Answered in this Report:
- What is a vector, and what is its importance in the medical industry? What are the major characteristics and types of vectors? What are the areas of application of vectors?
- What are the major advancements in viral and non-viral vector manufacturing? What are the key trends of the global viral and non-viral vector manufacturing market? How is the market evolving, and what is its future scope?
- What are the major drivers, challenges, and opportunities of the global viral and non-viral vector manufacturing market?
- What are the key developmental strategies implemented by the key players of the global viral and non-viral vector manufacturing market to sustain the competition of the market? What is the percentage share of each of the key players in different key developmental strategies?
- What is the regulatory scenario of the global viral and non-viral vector manufacturing market? What are the initiatives implemented by different governmental bodies and guidelines put forward to regulate the commercialization of viral and non-viral vector manufacturing products?
- What are major milestones in patenting activity in the global viral and non-viral vector manufacturing market?
- What was the market size of the global viral and non-viral vector manufacturing market in 2020, and what is the market size anticipated to be by 2031? What is the expected growth rate of the global viral and non-viral vector manufacturing market during the forecast period 2021-2031?
- What is the global market size for manufacturing different types of viral and non-viral vectors available in the global viral and non-viral vector manufacturing market? What are the key trends of the market with respect to different vectors, and which vector type is expected to dominate the market in 2031?
- What are the different disease areas where non-viral vectors and viral vectors are employed in the global viral and non-viral vector manufacturing market? Which disease type dominated the market in 2020 and is expected to dominate in 2031?
- What are the different applications associated with the viral vector and non-viral vector manufacturing? What was the contribution of each of the application areas in the global viral and non-viral vector manufacturing market in 2020, and what is it expected in 2031?
- Which region is expected to contribute the highest sales in the global viral and non-viral vector manufacturing market during the period 2021-2031? Which region and country carries the potential for the significant expansion of key companies for different viral and non-viral vector manufacturing? What are the leading countries of different regions that contribute significantly toward the growth of the viral and non-viral manufacturing market?
- What are the key players of the global viral and non-viral vector manufacturing market, and what are their roles in the market? What were the market shares of the key players in 2020?
Market Overview
The advent of advanced therapies, including gene therapy and cell therapy, which employ the use of vectors, has created a huge impact in the field of medicine in the past few decades. Therapies that require genetic modification, including the introduction of therapeutic deoxyribonucleic acid (DNA)/gene into a patient's body or cell, demonstrated tremendous potential for treating several fatal diseases, including cancer, Alzheimer's disease, Parkinson's disease, and rheumatoid arthritis, among others. Promising results displayed by these vector-based therapies in several preclinical and clinical studies have further emphasized the development and standardization of various viral and non-viral vectors to address unmet medical needs. The global viral and non-viral vector manufacturing market was valued at $1.50 billion in 2020 and is expected to reach $27.03 billion by 2031, witnessing a CAGR of 18.54% during the forecast period 2021-2031.
Known to reduce the cost of treatment and help decrease repeated administration of medications, viral vectors, and non-viral vectors have gained significant attention globally as a novel therapeutic approach for treating various critical diseases, thereby promoting a surge of investments in drug development and commercialization. Growing prominence of gene and cell therapy products (that utilize vectors) and increasing funding activities driving research related to vector-based therapies are the key driving factors fuelling the growth of the global viral and non-viral vector manufacturing market. Moreover, rising incidences of genetic disorders, cancers, and infectious diseases, coupled with the increasing number of clinical studies and robust pipeline of gene and cell therapy products as well as vector-based vaccines, are the additional driving factors encouraging market growth.
Competitive Landscape
The global viral and non-viral vector manufacturing market comprises well-established and newly emerging companies. Several companies are attempting to enter the market and sustain the competition by adopting synergistic activities and expanding their business by launching manufacturing capacities or developing proprietary viral and non-viral vector platforms.
In the past three years (2018-2020), the key market players of the global viral and non-viral vector manufacturing market witnessed majorly synergistic activities, business expansion, and funding activities. The inclination of companies toward synergies suggests that the companies are collaborating with viral and non-viral vector manufacturers to develop novel cell therapies, gene therapies, and vaccines for various diseases. The expansion of manufacturing capacities suggests that the companies are trying to fulfill the increased demand for vectors for cell and gene therapies.
Table of Contents
1 Product Definition
1.1 Product Definition
2 Scope of Study
2.1 Overview
2.2 Segmentation of the Global Viral and Non-Viral Vector Manufacturing Market
2.3 Assumptions and Limitations
2.4 Key Questions Answered in This Report
2.5 Base Year and Forecast Period
3 Research Methodology
3.1 Overview
4 Global Viral and Non-Viral Vector Manufacturing: Market Overview
4.1 Market Overview
4.2 Introduction to Vectors
4.3 Importance of Vectors
4.3.1 Viral Vectors
4.3.2 Non-Viral Vectors
4.4 Major Milestones in Vector Manufacturing
4.4.1 Manufacturing Process
4.4.1.1 Upstream Bioprocessing
4.4.1.2 Downstream Bioprocessing
4.5 Global Viral and Non-Viral Vector Manufacturing Market Size
4.6 Impact of COVID-19 on the Global Viral and Non-Viral Vector Manufacturing Market
4.6.1 Disruption of the Vector Manufacturing Industry Due to COVID-19 Crisis
4.6.2 COVID-19 Affecting the Supply Chain of Vector-Based Therapies
4.6.2.1 Effect on Cell Therapy
4.6.2.2 Effect on Gene Therapy
4.6.3 Interruption in Research and Clinical Development and Commercial Operation
4.6.3.1 Research and Clinical Development
4.6.3.2 Commercial Operation and Access
4.6.4 Effect of COVID-19 in Vaccine Manufacturing
4.6.5 Measures Taken to Address the Current Problem
4.6.6 Navigating Crisis Recovery and Looking to the Future
5 Market Dynamics
5.1 Impact Analysis
5.2 Overview
5.3 Market Drivers
5.3.1 Viral Vectors
5.3.1.1 Rapid Uptake of Viral Vector to Develop Innovative Therapies
5.3.1.2 Increasing Number of Clinical Studies for the Development of Gene Therapy
5.3.1.3 Favorable Funding Scenario for Vector-Based Therapies
5.3.2 Non-Viral Vectors
5.3.2.1 Increasing Adoption of Nucleic Acid Therapeutics
5.3.2.2 Rise in Synergistic Activities in the Market
5.4 Market Restraints
5.4.1 Viral Vectors
5.4.1.1 Unaffordable Cost of Gene Therapy
5.4.1.2 High Manufacturing Cost of Viral Vectors
5.4.1.3 Complications Associated with Large-Scale Production of Viral Vectors
5.4.2 Non-Viral Vectors
5.4.2.1 Low Transfection Efficiency
5.5 Market Opportunities
5.5.1 Viral Vectors
5.5.1.1 Rise in Demand for Synthetic Genes
5.5.1.2 Emergence of Next-Generation Vectors
5.5.2 Non-Viral Vectors
5.5.2.1 Limitation of Viral Vectors
6 Industry Analysis
6.1 Overview
6.2 Regulatory Scenario
6.3 Patent Landscape
7 Competitive Landscape
7.1 Overview
7.2 Key Development and Strategies
7.2.1 Synergistic Activities
7.2.2 Business Expansion
7.2.3 Product Launches
7.2.4 Mergers and Acquisitions
7.2.5 Other Development
7.3 Market Share Analysis (by Company), 2020
7.4 Growth Share Analysis
7.4.1 Growth Share Analysis of the Global Viral and Non-Viral Vector Manufacturing Market (by Company)
7.4.2 Growth Share Analysis of the Global Viral and Non-Viral Vector Manufacturing Market (by Vector Type)
8 Global Viral and Non-Viral Vector Manufacturing Market (by Vector Type)
8.1 Overview
8.2 Viral Vector
8.2.1 Adenoviral Vector
8.2.2 Retroviral Vector
8.2.3 Adeno-Associated Viral Vector
8.2.4 Lentiviral Vector
8.2.5 Vaccinia Viral Vector
8.2.6 Other Viral Vector
8.3 Non-Viral Vectors
8.3.1 Plasmid DNA
8.3.2 Lipid-Based Non-Viral Vector
8.3.3 Polymer-Based Non-Viral Vector
8.3.4 Other Non-Viral Vector (Peptide-Based and Hybrid/Combination)
9 Global Viral and Non-Viral Vector Manufacturing Market (by Disease)
9.1 Overview
9.2 Cancer
9.3 Genetic Disease
9.4 Infectious Disease
9.5 Cardiovascular Disease
9.6 Other Diseases
10 Global Viral and Non-Viral Vector Manufacturing Market (by Application)
10.1 Overview
10.2 Gene Therapy
10.2.1 Viral Vector
10.2.2 Non-Viral Vector
10.3 Vaccinology
10.3.1 Viral Vector
10.3.2 Non-Viral Vector
10.4 Cell Therapy
10.4.1 Viral Vector
10.4.2 Non-Viral Vector
10.5 Other Applications
10.5.1 Viral Vector
10.5.2 Non-Viral Vector
11 Global Viral and Non-Viral Vector Manufacturing Market (by Region)
11.1 Overview
11.2 North America
11.2.1 Overview
11.2.2 U.S.
11.2.2.1 Viral Vector
11.2.2.2 Non-Viral Vector
11.2.3 Canada
11.2.3.1 Viral Vector
11.2.3.2 Non-Viral Vector
11.3 Europe
11.3.1 Overview
11.3.2 Germany
11.3.2.1 Viral Vector
11.3.2.2 Non-Viral Vector
11.3.3 U.K.
11.3.3.1 Viral Vector
11.3.3.2 Non-Viral Vector
11.3.4 France
11.3.4.1 Viral Vector
11.3.4.2 Non-Viral Vector
11.3.5 Italy
11.3.5.1 Viral Vector
11.3.5.2 Non-Viral Vector
11.3.6 Switzerland
11.3.6.1 Viral Vector
11.3.6.2 Non-Viral Vector
11.3.7 Belgium
11.3.7.1 Viral Vector
11.3.7.2 Non-Viral Vector
11.3.8 Spain
11.3.8.1 Viral Vector
11.3.8.2 Non-Viral Vector
11.3.9 Rest-of-Europe
11.3.9.1 Viral Vector
11.3.9.2 Non-Viral Vector
11.4 Asia-Pacific
11.4.1 Overview
11.4.2 China
11.4.2.1 Viral Vector
11.4.2.2 Non-Viral Vector
11.4.3 Australia
11.4.3.1 Viral Vector
11.4.3.2 Non-Viral Vector
11.4.4 Japan
11.4.4.1 Viral Vector
11.4.4.2 Non-Viral Vector
11.4.5 India
11.4.5.1 Viral Vector
11.4.5.2 Non-Viral Vector
11.4.6 South Korea
11.4.6.1 Viral Vector
11.4.6.2 Non-Viral Vector
11.4.7 Singapore
11.4.7.1 Viral Vector
11.4.7.2 Non-Viral Vector
11.4.8 Rest-of-Asia-Pacific
11.4.8.1 Viral Vector
11.4.8.2 Non-Viral Vector
11.5 Rest-of-the-World
11.5.1 Overview
11.5.1.1 Viral Vector
11.5.1.2 Non-Viral Vector
12 Company Profiles
12.1 Overview
12.2 Boehringer Ingelheim
12.2.1 Company Overview
12.2.1.1 Role of Boehringer Ingelheim in the Global Viral and Non-Viral Vector Manufacturing Market
12.2.1.2 Product Portfolio
12.2.2 SWOT Analysis
12.3 Catalent, Inc.
12.3.1 Company Overview
12.3.1.1 Role of Catalent, Inc. in the Global Viral and Non-Viral Vector Manufacturing Market
12.3.1.2 Product Portfolio
12.3.2 Financials
12.3.3 Key Insights about Financial Health of the Company
12.3.4 SWOT Analysis
12.4 FUJIFILM Holdings Corporation
12.4.1 Company Overview
12.4.1.1 Role of FUJIFILM Holdings Corporation in the Global Viral and Non-Viral Vector Manufacturing Market
12.4.1.2 Product Portfolio
12.4.2 Financials
12.4.3 Key Insights about Financial Health of the Company
12.4.4 SWOT Analysis
12.5 Danaher Corporation
12.5.1 Company Overview
12.5.2 Role of Danaher Corporation in the Global Viral and Non-Viral Vector Manufacturing Market
12.5.2.1 Product Portfolio
12.5.3 Financials
12.5.4 Key Insights about Financial Health of the Company
12.5.5 SWOT Analysis
12.6 Genscript Biotech Corporation
12.6.1 Company Overview
12.6.1.1 Role of Genscript Biotech Corporation in the Global Viral and Non-Viral Vector Manufacturing Market
12.6.1.2 Product Portfolio
12.6.2 Financials
12.6.3 Key Insights about Financial Health of the Company
12.6.4 SWOT Analysis
12.7 Lonza Group AG
12.7.1 Company Overview
12.7.1.1 Role of Lonza Group AG in the Global Viral and Non-Viral Vector Manufacturing Market
12.7.1.2 Product Portfolio
12.7.2 Financials
12.7.3 Key Insights about Financial Health of the Company
12.7.4 SWOT Analysis
12.8 Merck KGaA Inc.
12.8.1 Company Overview
12.8.1.1 Role of Merck KGaA Inc. in the Global Viral and Non-Viral Vector Manufacturing Market
12.8.1.2 Product Portfolio
12.8.2 Financials
12.8.3 Key Insights about Financial Health of the Company
12.8.4 SWOT Analysis
12.9 Oxford Biomedica plc
12.9.1 Company Overview
12.9.1.1 Role of Oxford Biomedica plc in the Global Viral and Non-Viral Vector Manufacturing Market
12.9.1.2 Product Portfolio
12.9.2 Financials
12.9.3 Key Insights about Financial Health of the Company
12.9.4 SWOT Analysis
12.1 Sartorius AG
12.10.1 Company Overview
12.10.1.1 Role of Sartorius AG in the Global Viral and Non-Viral Vector Manufacturing Market
12.10.1.2 Product Portfolio
12.10.2 Financials
12.10.3 Key Insights about Financial Health of the Company
12.10.4 SWOT Analysis
12.11 Takara Bio Inc.
12.11.1 Company Overview
12.11.1.1 Role of Takara Bio Inc. in the Global Viral and Non-Viral Vector Manufacturing Market
12.11.1.2 Product Portfolio
12.11.2 Financials
12.11.3 Key Insights about Financial Health of the Company
12.11.4 SWOT Analysis
12.12 Thermo Fisher Scientific Inc.
12.12.1 Company Overview
12.12.1.1 Role of Thermo Fisher Scientific, Inc. in the Global Viral and Non-Viral Vector Manufacturing Market
12.12.1.2 Product Portfolio
12.12.2 Financials
12.12.3 Key Insights about Financial Health of the Company
12.12.4 SWOT Analysis
12.13 Wuxi AppTec
12.13.1 Company Overview
12.13.1.1 Role of Wuxi AppTec in Global Viral and Non-Viral Vector Manufacturing Market
12.13.1.2 Product Portfolio
12.13.2 Financials
12.13.3 Key Insights about Financial Health of the Company
12.13.4 SWOT Analysis
12.14 Acuitas Therapeutics
12.14.1 Company Overview
12.14.1.1 Role of Acuitas Therapeutics in the Global Viral and Non-Viral Vector Manufacturing Market
12.14.1.2 Product Portfolio
12.14.2 SWOT Analysis
12.15 Evonik Industries AG
12.15.1 Company Overview
12.15.1.1 Role of Evonik Industries AG in the Global Viral and Non-Viral Vector Manufacturing Market
12.15.1.2 Product Portfolio
12.15.2 Financials
12.15.3 Key Insights about Financial Health of the Company
12.15.4 SWOT Analysis
12.16 Exelead, Inc.
12.16.1 Company Overview
12.16.1.1 Role of Exelead, Inc. in the Global Viral and Non-Viral Vector Manufacturing Market
12.16.1.2 Product Portfolio
12.16.2 SWOT Analysis
12.17 Entos Pharmaceuticals
12.17.1 Company Overview
12.17.1.1 Role of Entos Pharmaceuticals in the Global Viral and Non-Viral Vector Manufacturing Market
12.17.1.2 Product Portfolio
12.17.2 SWOT Analysis
12.18 Genevant Sciences GmbH
12.18.1 Company Overview
12.18.1.1 Role of Genevant Sciences GmbH in the Global Viral and Non-Viral Vector Manufacturing Market
12.18.1.2 Product Portfolio
12.18.2 SWOT Analysis
12.19 T&T Scientific Corporation
12.19.1 Company Overview
12.19.1.1 Role of T&T Scientific Corporation in the Global Viral and Non-Viral Vector Manufacturing Market
12.19.1.2 Product Portfolio
12.19.2 SWOT Analysis
12.2 Moderna, Inc.
12.20.1 Company Overview
12.20.1.1 Role of Moderna, Inc. in the Global Viral and Non-Viral Vector Manufacturing Market
12.20.1.2 Product Portfolio
12.20.2 Financials
12.20.3 Key Insights about Financial Health of the Company
12.20.4 SWOT Analysis
12.21 CureVac N.V.
12.21.1 Company Overview
12.21.1.1 Role of CureVac N.V in the Global Viral and Non-Viral Vector Manufacturing Market
12.21.1.2 Product Portfolio
12.21.2 Financials
12.21.3 Key Insights about Financial Health of the Company
12.21.4 SWOT Analysis
List of Figures
Figure 1: Global Viral and Non-Viral Vector Manufacturing Market (by Region), 2020 and 2031
Figure 2: Key Players of the Global Viral and Non-Viral Vector Manufacturing Market
Figure 3: Drivers, Challenges, and Opportunities of the Global Viral Vector and Non-Viral Vector Manufacturing Market
Figure 4: Share of Key Developments and Strategies, January 2018-October 2021
Figure 5: Global Viral and Non-Viral Vector Manufacturing Market (by Vector Type), $Million, 2020 and 2031
Figure 6: Global Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031
Figure 7: Global Viral and Non-Viral Vector Manufacturing Market (by Disease), 2020 and 2031
Figure 8: Global Viral and Non-Viral Vector Manufacturing Market (by Application), 2020 and 2031
Figure 9: Global Viral and Non-Viral Vector Manufacturing Market Segmentation
Figure 10: Global Viral and Non-Viral Vector Manufacturing Market Research Methodology
Figure 11: Primary Research
Figure 12: Secondary Research
Figure 13: Data Triangulation
Figure 14: Bottom-Up Approach (Segment-Wise Analysis)
Figure 15: Top-Down Approach (Segment-Wise Analysis)
Figure 16: Assumptions and Limitations
Figure 17: Mechanism of Action of Vectors
Figure 18: Evolutionary History of Vectors
Figure 19: Typical Production Methods of Viral Vectors and Plasmids
Figure 20: Global Viral and Non-Viral Vector Manufacturing Market, $Billion, 2020-2031
Figure 21: Pre- COVID-19 and Post-COVID-19 Scenario of the Global Viral and Non-Viral Vector Manufacturing Market, 2017-2025
Figure 22: Long, Complex, and Highly Controlled Supply Chain of Cell Therapy
Figure 23: Less-Complex Supply Chain of Gene Therapy
Figure 24: Areas of Disruption in Cell Therapy Industry
Figure 25: Areas of Disruption in Gene Therapy Industry
Figure 26: Key Areas of Disruption in Commercial Operation
Figure 27: Measures to Navigate Crisis Recovery
Figure 28: Impact Analysis
Figure 29: Workflow Associated with Biomanufacturing for the Commercialization of Viral and Non-Viral Vector Products
Figure 30: Competitive Landscape, January 2018-October 2021
Figure 31: Share of Key Development and Strategy, January 2018-October 2021
Figure 32: Share of Synergistic Activities (by Company), January 2018-October 2021
Figure 33: Share of Business Expansion Activities (by Company), January 2018-October 2021
Figure 34: Share of Product Launches (by Company), January 2018-October 2021
Figure 35: Share of Mergers and Acquisitions (by Company), January 2018-October 2021
Figure 36: Share of Other Key Developments (by Company), January 2018-October 2021
Figure 37: Market Share Analysis of Global Viral and Non-Viral Vector Manufacturing Market (by Company), 2020
Figure 38: Growth Share Analysis for Global Viral and Non-Viral Vector Manufacturing Market (by Company), 2020
Figure 39: Growth Share Analysis for the Global Viral and Non-Viral Vector Manufacturing Market (by Vector Type), 2020
Figure 40: Global Viral and Non-Viral Vector Manufacturing Market Segmentation (by Vector Type)
Figure 41: Global Viral and Non-Viral Vector Manufacturing Market (by Viral and Non-Viral Vector), $Million, 2020 and 2031
Figure 42: Global Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020-2031
Figure 43: Global Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031
Figure 44: Global Viral and Non-Viral Vector Manufacturing Market for Adenoviral Vector $Million, 2020-2031
Figure 45: Global Viral and Non-Viral Vector Manufacturing Market for Retroviral Vector $Million, 2020-2031
Figure 46: Global Viral and Non-Viral Vector Manufacturing Market for Adeno-Associated Viral Vector, $Million, 2020-2031
Figure 47: Global Viral and Non-Viral Vector Manufacturing Market for Lentiviral Vector, 2020-2031
Figure 48: Global Viral and Non-Viral Vector Manufacturing Market for Vaccinia Viral Vector, $Million, 2020-2031
Figure 49: Global Viral and Non-Viral Vector Manufacturing Market for Other Viral Vector, $Million, 2020-2031
Figure 50: Global Viral and Non-Viral Vector Manufacturing Market for Non-Viral Vectors, 2020-2031
Figure 51: Global Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million, 2020 and 2031
Figure 52: Global Viral and Non-Viral Vector Manufacturing Market for Plasmid DNA, $Million, 2020-2031
Figure 53: Different Types of Lipid-Based Non-Viral Vectors
Figure 54: Viral and Non-Viral Vector Manufacturing Market for Lipid-Based Non-Viral Vectors, $Million, 2020-2031
Figure 55: Different Types of Polymers Used as Delivery Systems
Figure 56: Viral and Non-Viral Vector Manufacturing Market for Polymer-Based Non-Viral Vector, $Million, 2020-2031
Figure 57: Viral and Non-Viral Vector Manufacturing Market for Other Non-Viral Vector, $Million, 2020-2031
Figure 58: Global Viral and Non-Viral Vector Manufacturing Market Segmentation (by Disease)
Figure 59: Global Viral and Non-Viral Vector Manufacturing Market (by Disease)
Figure 60: Global Viral and Non-Viral Vector Manufacturing Market for Cancer, $Million, 2020-2031
Figure 61: List of Approved Human Gene Transfer Trials for Monogenic Disorders
Figure 62: Global Viral and Non-Viral Vector Manufacturing Market for Genetic Disease, $Million, 2020-2031
Figure 63: Global Viral and Non-Viral Vector Manufacturing Market for Infectious Disease, $Million, 2020-2031
Figure 64: Global Viral and Non-Viral Vector Manufacturing Market for Cardiovascular Disease, $Million, 2020-2031
Figure 65: Global Viral and Non-Viral Vector Manufacturing Market for Other Diseases, 2020-2031
Figure 66: Global Viral and Non-Viral Vector Manufacturing Market Segmentation (by Application)
Figure 67: Global Viral and Non-Viral Vector Manufacturing Market (by Application), 2020 and 2031
Figure 68: Global Viral and Non-Viral Vector Manufacturing Market for Gene Therapy, $Million, 2020-2031
Figure 69: Gene Therapy: Viral Vs. Non-Viral Vector Manufacturing Market, $Million, 2020-2031
Figure 70: Global Viral and Non-Viral Vector Manufacturing Market for Gene Therapy (by Viral Vector), $Million, 2020 and 2031
Figure 71: Global Viral and Non-Viral Vector Manufacturing Market for Gene Therapy (by Non-Viral Vector), $Million, 2020 and 2031
Figure 72: Global Viral and Non-Viral Vector Manufacturing Market for Vaccinology, $Million, 2020-2031
Figure 73: Vaccinology: Viral Vs. Non-Viral Vector Manufacturing Market, $Million, 2020-2031
Figure 74: Global Viral and Non-Viral Vector Manufacturing Market for Vaccinology (by Viral Vector), $Million, 2020 and 2031
Figure 75: Global Viral and Non-Viral Vector Manufacturing Market for Vaccinology (by Non-Viral Vector), 2020 and 2031
Figure 76: Global Viral and Non-Viral Vector Manufacturing Market for Cell Therapy, $Million, 2020-2031
Figure 77: Cell Therapy: Viral Vs. Non-Viral Vector Manufacturing Market, $Million, 2020-2031
Figure 78: Global Viral and Non-Viral Vector Manufacturing Market for Cell Therapy (by Viral Vector), $Million, 2020 and 2031
Figure 79: Global Viral and Non-Viral Vector Manufacturing Market for Cell Therapy (by Non-Viral Vector), $Million, 2020 and 2031
Figure 80: Global Viral and Non-Viral Vector Manufacturing Market for Other Applications, $Million, 2020-2031
Figure 81: Other Applications: Viral Vs. Non-Viral Vector Manufacturing Market, $Million, 2020-2031
Figure 82: Global Viral and Non-Viral Vector Manufacturing Market for Other Applications (by Viral Vector), $Million, 2020 and 2031
Figure 83: Global Viral and Non-Viral Vector Manufacturing Market for Other Applications (by Non-Viral Vector), $Million, 2020 and 2031
Figure 84: North America: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
Figure 85: U.S.: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
Figure 86: U.S.: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), $Million, 2020-2031
Figure 87: U.S.: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031
Figure 88: U.S.: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million, 2020 and 2031
Figure 89: Canada: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
Figure 90: Canada: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), $Million, 2020-2031
Figure 91: Canada: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031
Figure 92: Canada: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million, 2020 and 2031
Figure 93: Europe: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
Figure 94: Germany: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
Figure 95: Germany: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), $Million, 2020-2031
Figure 96: Germany: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031
Figure 97: Germany: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million, 2020 and 2031
Figure 98: U.K.: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
Figure 99: U.K.: Viral Vs Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), $Million, 2020-2031
Figure 100: U.K.: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031
Figure 101: U.K.: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million, 2020 and 2031
Figure 102: France: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
Figure 103: France: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), $Million, 2020-2031
Figure 104: France: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031
Figure 105: France: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million, 2020 and 2031
Figure 106: Italy: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
Figure 107: Italy: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), 2020-2031
Figure 108: Italy: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031
Figure 109: Italy: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million, 2020 and 2031
Figure 110: Switzerland: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
Figure 111: Switzerland: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), $Million, 2020-2031
Figure 112: Switzerland: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031
Figure 113: Switzerland: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million, 2020 and 2031
Figure 114: Belgium: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
Figure 115: Belgium: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), $Million, 2020-2031
Figure 116: Belgium: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031
Figure 117: Belgium: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), 2020 and 2031
Figure 118: Spain: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
Figure 119: Spain: Viral and Non-Viral Vector Manufacturing Market, (Viral Vs. Non-Viral), $Million, 2020-2031
Figure 120: Spain: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031
Figure 121: Spain: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million, 2020 and 2031
Figure 122: Rest-of-Europe: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
Figure 123: Rest-of-Europe: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), $Million, 2020-2031
Figure 124: Rest-of-Europe: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031
Figure 125: Rest-of-Europe: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million, 2020 and 2031
Figure 126: Asia-Pacific: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
Figure 127: China: Viral Vector and Non-Viral Vector Manufacturing Market, $Million 2020-2031
Figure 128: China: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), $Million, 2020-2031
Figure 129: China: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031
Figure 130: China: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million, 2020 and 2031
Figure 131: Australia: Viral Vector and Non-Viral Vector Manufacturing Market, $Million 2020-2031
Figure 132: Australia: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), $Million, 2020-2031
Figure 133: Australia: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031
Figure 134: Australia: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million, 2020 and 2031
Figure 135: Japan: Viral Vector and Non-Viral Vector Manufacturing Market, $Million 2020-2031
Figure 136: Japan: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), $Million, 2020-2031
Figure 137: Japan: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031
Figure 138: Japan: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million, 2020 and 2031
Figure 139: India: Viral Vector and Non-Viral Vector Manufacturing Market, $Million 2020-2031
Figure 140: India: Viral vs Non-Viral Vector Manufacturing Market, $Million, 2020-2031
Figure 141: India: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031
Figure 142: India: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million, 2020 and 2031
Figure 143: South Korea: Viral Vector and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
Figure 144: South Korea: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), $Million, 2020-2031
Figure 145: South Korea: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031
Figure 146: South Korea: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million, 2020 and 2031
Figure 147: Singapore: Viral Vector and Non-Viral Vector Manufacturing Market, $Million 2020-2031
Figure 148: Singapore: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), $Million, 2020-2031
Figure 149: Singapore: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031
Figure 150: Singapore: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million, 2020-2031
Figure 151: Rest-of-Asia-Pacific: Viral Vector and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
Figure 152: Rest-of-Asia-Pacific: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral Vector), $Million, 2020-2031
Figure 153: Rest-of-Asia-Pacific: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031
Figure 154: Rest-of-Asia-Pacific: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million, 2020 and 2031
Figure 155: Rest-of-the-World Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
Figure 156: Rest-of-the-World: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), $Million, 2020-2031
Figure 157: Rest-of-the-World: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031
Figure 158: Rest-of-the-World: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million, 2020 and 2031
Figure 159: Shares of Key Company Profiles
Figure 160: Boehringer Ingelheim: Service Portfolio
Figure 161: Boehringer Ingelheim: SWOT Analysis
Figure 162: Catalent, Inc.: Service/Product Portfolio
Figure 163: Catalent, Inc.: Overall Financials, $Million, 2019-2021
Figure 164: Catalent, Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 165: Catalent, Inc.: Revenue (by Region), $Million, 2019-2021
Figure 166: Catalent, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 167: Catalent, Inc.: SWOT Analysis
Figure 168: FUJIFILM Holdings Corporation: Service/Product Portfolio
Figure 169: FUJIFILM Holdings Corporation: Overall Financials, $Million, 2018-2020
Figure 170: FUJIFILM Holdings Corporation: Revenue (by Segment), $Million, 2018-2020
Figure 171: FUJIFILM Holdings Corporation: Revenue (by Region), $Million, 2018-2020
Figure 172: FUJIFILM Holdings Corporation: R&D Expenditure, $Million, 2018-2020
Figure 173: FUJIFILM Holdings Corporation: SWOT Analysis
Figure 174: Danaher Corporation: Service/Product Portfolio
Figure 175: Danaher Corporation: Overall Financials, $Million, 2018-2020
Figure 176: Danaher Corporation: Revenue (by Segment), $Million, 2018-2020
Figure 177: Danaher Corporation: Revenue (by Region), $Million, 2018-2020
Figure 178: Danaher Corporation: R&D Expenditure, $Million, 2018-2020
Figure 179: Danaher Corporation: SWOT Analysis
Figure 180: Genscript Biotech Corporation: Service/Product Portfolio
Figure 181: Genscript Biotech Corporation: Overall Financials, $Million, 2018-2020
Figure 182: Genscript Biotech Corporation: Revenue (by Segment), $Million, 2018-2020
Figure 183: Genscript Biotech Corporation: Revenue (by Region), $Million, 2018-2020
Figure 184: Genscript Biotech Corporation: R&D Expenditure, $Million, 2018-2020
Figure 185: Genscript Biotech Corporation: SWOT Analysis
Figure 186: Lonza Group AG: Service/Product Portfolio
Figure 187: Lonza Group AG: Overall Financials, $Million, 2018-2020
Figure 188: Lonza Group AG: Revenue (by Segment), $Million, 2018-2020
Figure 189: Lonza Group AG: Revenue (by Region), $Million, 2018-2020
Figure 190: Lonza Group AG: R&D Expenditure, $Million, 2018-2020
Figure 191: Lonza Group AG: SWOT Analysis
Figure 192: Merck KGaA Inc.: Service/Product Portfolio
Figure 193: Merck KGaA Inc.: Overall Financials, $Million, 2018-2020
Figure 194: Merck KGaA Inc.: Revenue (by Segment), $Million, 2018-2020
Figure 195: Merck KGaA Inc.: Revenue (by Region), $Million, 2018-2020
Figure 196: Merck KGaA Inc.: R&D Expenditure, $Million, 2018-2020
Figure 197: Merck KGaA Inc.: SWOT Analysis
Figure 198: Oxford Biomedica plc: Service/Product Portfolio
Figure 199: Oxford Biomedica plc: Overall Financials, $Million, 2018-2020
Figure 200: Oxford Biomedica plc: Revenue (by Segment), $Million, 2018-2020
Figure 201: Oxford Biomedica plc: Revenue (by Region), $Million, 2018-2020
Figure 202: Oxford Biomedica plc: R&D Expenditure, $Million, 2018-2020
Figure 203: Oxford Biomedica plc: SWOT Analysis
Figure 204: Sartorius AG: Service/Product Portfolio
Figure 205: Sartorius AG: Overall Financials, $Million, 2018-2020
Figure 206: Sartorius AG: Revenue (by Segment), $Million, 2018-2020
Figure 207: Sartorius AG: Revenue (by Region), $Million, 2018-2020
Figure 208: Sartorius AG: R&D Expenditure, $Million, 2018-2020
Figure 209: Sartorius AG: SWOT Analysis
Figure 210: Takara Bio Inc.: Service/Product Portfolio
Figure 211: Takara Bio Inc.: Overall Financials, $Million, 2018-2020
Figure 212: Takara Bio Inc.: Revenue (by Segment), $Million, 2018-2020
Figure 213: Takara Bio Inc.: Revenue (by Region), $Million, 2018-2020
Figure 214: Takara Bio Inc.: R&D Expenditure, $Million, 2018-2020
Figure 215: Takara Bio Inc.: SWOT Analysis
Figure 216: Thermo Fisher Scientific, Inc.: Service/Product Portfolio
Figure 217: Thermo Fisher Scientific, Inc.: Overall Financials, $Million, 2018-2020
Figure 218: Thermo Fisher Scientific, Inc.: Revenue (by Segment), $Million, 2018-2020
Figure 219: Thermo Fisher Scientific, Inc.: Revenue (by Region), $Million, 2018-2020
Figure 220: Thermo Fisher Scientific, Inc.: R&D Expenditure, $Million, 2018-2020
Figure 221: Thermo Fisher Scientific, Inc.: SWOT Analysis
Figure 222: Wuxi AppTec: Service/Product Portfolio
Figure 223: Wuxi AppTec: Overall Financials, $Million, 2018-2020
Figure 224: Wuxi AppTec: Revenue (by Segment), $Million, 2018-2020
Figure 225: Wuxi AppTec: Revenue (by Region), $Million, 2018-2020
Figure 226: Wuxi AppTec: R&D Expenditure, $Million, 2018-2020
Figure 227: Wuxi AppTec: SWOT Analysis
Figure 228: Acuitas Therapeutics: Service/Product Portfolio
Figure 229: Acuitas Therapeutics: SWOT Analysis
Figure 230: Evonik Industries AG: Service/Product Portfolio
Figure 231: Evonik Industries AG: Overall Financials, $Million, 2018-2020
Figure 232: Evonik Industries AG: Revenue (by Segment), $Million, 2018-2020
Figure 233: Evonik Industries AG: Revenue (by Region), $Million, 2018-2020
Figure 234: Evonik Industries AG: R&D Expenditure, $Million, 2018-2020
Figure 235: Evonik Industries AG: SWOT Analysis
Figure 236: Exelead, Inc.: Service/Product Portfolio
Figure 237: Exelead, Inc.: SWOT Analysis
Figure 238: Entos Pharmaceuticals: Service/Product Portfolio
Figure 239: Entos Pharmaceuticals: SWOT Analysis
Figure 240: Genevant Sciences GmbH: Service/Product Portfolio
Figure 241: Genevant Sciences GmbH: SWOT Analysis
Figure 242: T&T Scientific Corporation: Service/Product Portfolio
Figure 243: T&T Scientific Corporation: SWOT Analysis
Figure 244: Moderna, Inc.: Service/Product Portfolio
Figure 245: Moderna, Inc.: Overall Financials, $Million, 2018-2020
Figure 246: Moderna, Inc.: Revenue (by Region), $Million, 2018-2020
Figure 247: Moderna, Inc.: R&D Expenditure, $Million, 2018-2020
Figure 248: Moderna, Inc.: SWOT Analysis
Figure 249: CureVac N.V.: Product Portfolio
Figure 250: CureVac N.V.: Overall Financials, $Million, 2018-2020
Figure 251: CureVac N.V.: Revenue (by Region), $Million, 2018-2020
Figure 252: CureVac N.V.: R&D Expenditure, $Million, 2018-2020
Figure 253: CureVac N.V.: SWOT Analysis
List of Tables
Table 1: Leading Segments of the Global Viral and Non-Viral Vector Manufacturing Market, 2020 and 2031
Table 2: Advantages and Disadvantages of Viral Vectors
Table 3: Advantages and Disadvantages of Non-Viral Vectors
Table 4: COVID-19 Candidate Viral Vector Vaccines in Clinical Stage (as of 31st July 2020)
Table 5: COVID-19 Candidate Viral Vector Vaccines in Preclinical Stage (as of 31 July 2020)
Table 6: Recent Approvals for Gene Therapy
Table 7: Companies Offering Gene Therapies and Their Cost
Table 8: Global Regulatory Scenario
Table 9: Patents Related to Viral Vectors (January 2018-February 2021)
Table 10: Patents Related to Non-Viral Vectors (January 2018-February 2021)
Table 11: Examples of Viral Vectors Used in Gene Therapy
Table 12: List of Non-Viral Vector-Based Vaccines against Infectious Diseases
Table 13: Features of Vectors Used in Cardiovascular Therapy
Table 14: Examples of Clinical Trials Using Viral Vectors
Table 15: List of Clinical Trials Using Non-Viral Vectors
Table 16: Advantages and Disadvantages Associated with Major Viral Vectors
Companies Mentioned
- Boehringer Ingelheim
- Catalent, Inc.
- FUJIFILM Holdings Corporation
- Danaher Corporation
- Genscript Biotech Corporation
- Lonza Group AG
- Merck KGaA Inc.
- Oxford Biomedica plc
- Sartorius AG
- Takara Bio Inc.
- Thermo Fisher Scientific Inc.
- Wuxi AppTec
- Acuitas Therapeutics
- Evonik Industries AG
- Exelead, Inc.
- Entos Pharmaceuticals
- Genevant Sciences GmbH
- T&T Scientific Corporation
- Moderna, Inc.
- CureVac N.V.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 286 |
| Published | December 2021 |
| Forecast Period | 2021 - 2031 |
| Estimated Market Value ( USD | $ 4.93 Billion |
| Forecasted Market Value ( USD | $ 27.03 Billion |
| Compound Annual Growth Rate | 18.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 20 |
